(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.21% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Haleon's revenue in 2025 is $14,588,311,688.On average, 4 Wall Street analysts forecast HLN's revenue for 2025 to be $132,319,156,395,046, with the lowest HLN revenue forecast at $130,825,092,407,067, and the highest HLN revenue forecast at $133,751,233,037,354. On average, 3 Wall Street analysts forecast HLN's revenue for 2026 to be $139,124,493,095,317, with the lowest HLN revenue forecast at $136,352,993,815,074, and the highest HLN revenue forecast at $140,854,525,031,494.
In 2027, HLN is forecast to generate $145,620,210,997,638 in revenue, with the lowest revenue forecast at $141,897,881,790,550 and the highest revenue forecast at $149,174,763,787,002.